Nomura Asset Management Co. Ltd. Boosts Stock Position in Zoetis Inc. $ZTS

Nomura Asset Management Co. Ltd. boosted its holdings in Zoetis Inc. (NYSE:ZTS) by 24.3% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 582,128 shares of the company’s stock after purchasing an additional 113,648 shares during the quarter. Nomura Asset Management Co. Ltd.’s holdings in Zoetis were worth $73,243,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of the business. Nordea Investment Management AB grew its holdings in shares of Zoetis by 79.2% during the fourth quarter. Nordea Investment Management AB now owns 4,932,787 shares of the company’s stock worth $622,222,000 after purchasing an additional 2,179,578 shares during the last quarter. Seilern Investment Management Ltd grew its holdings in shares of Zoetis by 361.2% during the fourth quarter. Seilern Investment Management Ltd now owns 333,465 shares of the company’s stock worth $41,957,000 after purchasing an additional 261,155 shares during the last quarter. Assenagon Asset Management S.A. grew its holdings in shares of Zoetis by 134.4% during the fourth quarter. Assenagon Asset Management S.A. now owns 1,631,619 shares of the company’s stock worth $205,290,000 after purchasing an additional 935,432 shares during the last quarter. Prudential PLC grew its holdings in shares of Zoetis by 17.7% during the third quarter. Prudential PLC now owns 197,852 shares of the company’s stock worth $28,950,000 after purchasing an additional 29,702 shares during the last quarter. Finally, AE Wealth Management LLC grew its holdings in shares of Zoetis by 71.3% during the fourth quarter. AE Wealth Management LLC now owns 144,531 shares of the company’s stock worth $18,185,000 after purchasing an additional 60,167 shares during the last quarter. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Zoetis Price Performance

Shares of ZTS opened at $77.81 on Friday. Zoetis Inc. has a fifty-two week low of $72.38 and a fifty-two week high of $172.23. The company has a market capitalization of $32.62 billion, a price-to-earnings ratio of 12.90, a price-to-earnings-growth ratio of 1.27 and a beta of 0.87. The firm has a 50-day simple moving average of $104.29 and a 200-day simple moving average of $117.03. The company has a debt-to-equity ratio of 2.80, a quick ratio of 1.91 and a current ratio of 3.15.

Zoetis (NYSE:ZTS) last announced its earnings results on Thursday, May 7th. The company reported $1.53 earnings per share for the quarter, missing the consensus estimate of $1.60 by ($0.07). Zoetis had a return on equity of 66.85% and a net margin of 27.80%.The business had revenue of $2.26 billion for the quarter, compared to analyst estimates of $2.30 billion. During the same quarter last year, the company posted $1.48 EPS. Zoetis’s quarterly revenue was up 2.9% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. On average, equities research analysts anticipate that Zoetis Inc. will post 6.89 earnings per share for the current year.

Zoetis Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Monday, July 20th will be paid a dividend of $0.53 per share. The ex-dividend date is Monday, July 20th. This represents a $2.12 annualized dividend and a dividend yield of 2.7%. Zoetis’s dividend payout ratio is 35.16%.

Analysts Set New Price Targets

Several equities analysts have issued reports on the company. Argus reaffirmed a “hold” rating on shares of Zoetis in a report on Wednesday. UBS Group dropped their price objective on Zoetis from $130.00 to $99.00 and set a “neutral” rating on the stock in a report on Friday, May 8th. JPMorgan Chase & Co. dropped their price objective on Zoetis from $190.00 to $130.00 and set an “overweight” rating on the stock in a report on Friday, May 8th. Stifel Nicolaus dropped their price objective on Zoetis from $105.00 to $95.00 and set a “hold” rating on the stock in a report on Friday, May 22nd. Finally, BTIG Research reaffirmed a “buy” rating and set a $160.00 price objective on shares of Zoetis in a report on Thursday, February 26th. Six investment analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Zoetis currently has an average rating of “Hold” and a consensus target price of $133.92.

Insider Transactions at Zoetis

In other news, Director Michael B. Mccallister acquired 3,000 shares of Zoetis stock in a transaction that occurred on Monday, May 11th. The stock was purchased at an average price of $77.76 per share, for a total transaction of $233,280.00. Following the completion of the transaction, the director directly owned 24,524 shares in the company, valued at approximately $1,906,986.24. This trade represents a 13.94% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Paul Bisaro acquired 2,000 shares of Zoetis stock in a transaction that occurred on Wednesday, May 13th. The stock was purchased at an average price of $75.88 per share, with a total value of $151,760.00. Following the transaction, the director owned 27,862 shares of the company’s stock, valued at $2,114,168.56. This trade represents a 7.73% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Over the last quarter, insiders acquired 11,650 shares of company stock worth $886,384. Company insiders own 0.22% of the company’s stock.

Key Headlines Impacting Zoetis

Here are the key news stories impacting Zoetis this week:

• Positive Sentiment: Zoetis presented at the Stifel Jaws & Paws Conference, which may have helped keep some investor attention on the company’s long-term animal health growth story. Zoetis Inc. (ZTS) Presents at Stifel Jaws & Paws Conference 2026 Transcript
• Neutral Sentiment: Brokerage coverage now shows a consensus “Hold” rating on Zoetis, suggesting analysts see limited near-term upside or downside from current levels. Zoetis Inc. (NYSE:ZTS) Receives Consensus Rating of “Hold” from Brokerages
• Negative Sentiment: Argus Research downgraded Zoetis, adding to concerns that Wall Street’s view on the stock is softening. Argus Research downgrades Zoetis (ZTS)
• Negative Sentiment: Multiple law firms announced or promoted a securities class action tied to Zoetis, which can weigh on sentiment because it raises legal and reputational risk for the company. ZTS INVESTOR ALERT: Zoetis Inc. Investors with Substantial Losses Have Opportunity to Lead the Zoetis Class Action Lawsuit

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.